Calcium channel blockers and myocardial infarction: A case-control study in a Japanese hospital

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 6, 2002, Pages 487-492

  Ohyama, Yoshiharu ^a   Funao, Kazuhiro ^a   Kawabe, Eri ^b   Hayashi, Doubun ^b   Yamazaki, Tsutomu ^b   Iga, Tatsuji ^c   Koide, Daisuke ^c   Ohe, Kazuhiko ^c   Kubota, Kiyoshi ^b  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Calcium channel blockers; Case control study; Confounding by indication; Hospital information system; Myocardial infarction

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NICARDIPINE; NIFEDIPINE; NILVADIPINE;

ADULT; AGE; AGED; ANAMNESIS; ANGINA PECTORIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG USE; EUROPE; FATALITY; FEMALE; GENDER; HEALTH SERVICE; HEART INFARCTION; HOSPITAL INFORMATION SYSTEM; HUMAN; HYPERTENSION; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; FEMALE; HOSPITAL INFORMATION SYSTEMS; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO;

EID: 0036751050     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.743     Document Type: Article

References (19)

1. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995; 274: 620-625.
2. Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 356: 1955-1964.
3. Pahor M, Psaty BM, et al. Health outcomes associated with calcium antagonists compared with other first-line anti-hypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000; 356: 1949-1954.
4. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. JAMA 1995; 274: 654-655.
5. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995; 123: 888-889.
6. Barnett AA. FDA committee rules calcium channel blockers safe. Lancet 1996; 347: 313.
7. Leor J, Battler A. Calcium channel blocker debate: true lies. Cardiovasc Drug Ther 1996; 10: 413-415.
8. Opie LH. Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease. Cardiovasc Drug Ther 1996; 10: 455-461.
9. Chobanian AV. Calcium channel blockers: lessons learned from MIDAS and other clinical trials. JAMA 1996; 276: 829-830.
10. Muratani H, Fukiyama K, Kamiyama T, et al. Current status of anti-hypertensive therapy for elderly patients in Japan. Hypertens Res 1996; 19: 281-290.
11. Ohe K, Kaihara S. Implementation of HL7 to client-server hospital information system (HIS) in the University of Tokyo Hospital. J Med Systems 1996; 20: 197-205.
12. Campbell JC, Ikegami N. The Art of Balance in Health Policy: Maintaining Japan's Low-Cost, Egalitarian System. Cambridge University Press: Cambridge, 1998.
13. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1227-1245.
14. SAS/STAT User's Guide Version 6 Fourth Edition. SAS Institute Incorporated, 1992.
15. Kernan WN, Viscoli CM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1827-1832.
16. Haffner SM, Lehto SL, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
17. Miwa K, Nakagawa K. Risk factors that discriminate 'high-risk' from 'low-risk' Japanese patients with coronary artery disease. Jpn Circ J 2000; 64: 825-830.
18. Guideline Subcommittee of Japanese Society of Hypertension. Guidelines for the Management of Hypertension. Japanese Society of Hypertension: Tokyo, 2000 (in Japanese).
19. Ministry of Health and Welfare, Japan Medical Association. Guidance for the Management of Hypertension Nihon-Ijishinpo: Tokyo, 1990 (in Japanese).